{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:26:32Z","timestamp":1697325992351},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1007\/s00105-007-1338-5","type":"journal-article","created":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T11:07:39Z","timestamp":1178795259000},"page":"515-524","source":"Crossref","is-referenced-by-count":1,"title":["Systemische Psoriasistherapie \u2013 der n\u00e4chste Schritt"],"prefix":"10.1007","volume":"58","author":[{"given":"G.","family":"Wozel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1338_CR1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.MIB.0000186489.53493.8a","volume":"12","author":"Aberra","year":"2006","unstructured":"Aberra FN (2006) To be or not to be: Infliximab during pregnancy? Inflamm Bowel Dis 12: 76\u201378","journal-title":"Inflamm Bowel Dis"},{"key":"1338_CR2","unstructured":"(2005) Adalimumab. In: McEvoy GK, Snow EK et al. (eds) AHFS Drug Information, American Society of Health-System Pharmacists. Bethesda, pp\u00a03620\u20132623"},{"key":"1338_CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","volume":"317","author":"Baecklund","year":"1998","unstructured":"Baecklund E, Ekborn A, Spar\u00e9n P et al. (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 317: 180\u2013181","journal-title":"Br Med J"},{"key":"1338_CR4","unstructured":"Blum R, Lebwohl M, Wong V et al. (2005) Durability of treatment response in patients with moderate to severe psoriasis following withdrawal from or a dose reduction in adalimumab therapy. J Am Acad Dermatol 52 [Suppl]: P2737"},{"key":"1338_CR5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/art.20763","volume":"52","author":"Bongartz","year":"2005","unstructured":"Bongartz T, H\u00e4rle P, Friedrich S et al. (2005) Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum 52: 280\u2013282","journal-title":"Arthritis Rheum"},{"key":"1338_CR6","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295: 2275\u20132285","journal-title":"JAMA"},{"key":"1338_CR7","unstructured":"Bonish BK, Patel T, Hoffman R et al. (2005) STAT3 is activated in psoriatic plaques and rapidly reduced following treatment with anti-TNF\u03b1 monoclonal antibody, adalimumab. The 66th Annual Meeting of the Society for Investigative Dermatology, St. Louis, USA, May 04-07"},{"key":"1338_CR8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2133.2004.06105.x","volume":"151","author":"Chew","year":"2004","unstructured":"Chew AL, Bennett A, Smith CH et al. (2004) Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 151: 492\u2013496","journal-title":"Br J Dermatol"},{"key":"1338_CR9","doi-asserted-by":"crossref","unstructured":"Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis [Suppl 4] 64: 18\u201323","DOI":"10.1136\/ard.2005.042549"},{"key":"1338_CR10","first-page":"S57","volume":"41","author":"Broeder","year":"1998","unstructured":"Broeder AA den, Wanten GJA, Riel PLCM van et al. (1998) The effect of D2E7, a new human anti-TNF\u03b1 monoclonal antibody, on the oxidative burst of PMN in patients with RA. Arthritis Rheum 41: S57","journal-title":"Arthritis Rheum"},{"key":"1338_CR11","first-page":"223","volume":"143","author":"Gannes","year":"2007","unstructured":"Gannes GC de, Ghoreishi M, Pope J et al. (2007) Psoriasis and pustular dermatitis triggered by TNF-\u03b1 inhibitors in patients with rheumatologic conditions. Arch Dermatol 143: 223\u2013231","journal-title":"Arch Dermatol"},{"key":"1338_CR12","first-page":"online","volume":"28","author":"DeRuiter","year":"2003","unstructured":"DeRuiter J, Riley TN (2003) How can Adalimumab (Humira\u00ae) be used to treat rheumatoid arthritis? Pharmacist 28: online publiziert","journal-title":"Pharmacist"},{"key":"1338_CR13","unstructured":"Estrach C, Mpofu S, Moots RJ (2003) Efficacy and safety of infliximab and adalimumab in Behcet\u2019s syndrome. 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, Florida, October 23\u201328"},{"key":"1338_CR14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archderm.143.2.233","volume":"143","author":"Fiorentino","year":"2007","unstructured":"Fiorentino DF (2007) The Yin and Yang of TNF-\u03b1 inhibition. Arch Dermatol 143: 233\u2013236","journal-title":"Arch Dermatol"},{"key":"1338_CR15","unstructured":"Foeldvari I, K\u00fcmmerle-Deschner J, Horneff G et al. (2005) Results of a multinational survey regarding the use of tumor necrosis factor alfa blocker in the treatment of juvenile idiopathic arthritis associated severe uveitis. EULAR, Wien. http:\/\/www.eular.org"},{"key":"1338_CR16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2133.2005.06816.x","volume":"153","author":"Gordon","year":"2005","unstructured":"Gordon KB, Bonish BK, Patel T et al. (2005) The tumour necrosis factor-\u03b1 inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153: 945\u2013953","journal-title":"Br J Dermatol"},{"key":"1338_CR17","first-page":"17","volume":"142","author":"Heffernan","year":"2006","unstructured":"Heffernan MP, Smith DI (2006) Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142: 17\u201319","journal-title":"Arch Dermatol"},{"key":"1338_CR18","unstructured":"Humira\u00ae 40\u00a0mg Injektionsl\u00f6sung in Fertigspritze. Fachinformation Juni 2006"},{"key":"1338_CR19","unstructured":"Humira\u00ae Produktmonographie Oktober 2003"},{"key":"1338_CR20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00001574-200407000-00005","volume":"20","author":"Katz","year":"2004","unstructured":"Katz JA (2004) Pregnancy and inflammatory bowel disease. Curr Opin Gastroenterol 20: 328\u2013332","journal-title":"Curr Opin Gastroenterol"},{"key":"1338_CR21","doi-asserted-by":"crossref","unstructured":"Kempeni J (1999) Preliminary results of early clinical trials with the fully human anti-TNF\u03b1 monoclonal antibody D2E7. Ann Rheum Dis [Suppl I] 58: 170\u2013172","DOI":"10.1136\/ard.58.2008.i70"},{"key":"1338_CR22","unstructured":"Kohno T, Stevens S, Louie J (2005) Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. J Am Acad Dermatol 52 [Suppl]: P400"},{"key":"1338_CR23","unstructured":"Langley R, Leonardi C, Toth D, Hoffman R (2005) Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. AAD, Annual Scientific Meeting, San Diego, California, November 12\u201317"},{"key":"1338_CR24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","volume":"21","author":"Mahadevan","year":"2005","unstructured":"Mahadevan U, Kane S, Sandborn WJ et al. (2005) Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn\u2019s disease. Aliment Pharmacol Ther 21: 733\u2013738","journal-title":"Aliment Pharmacol Ther"},{"key":"1338_CR25","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1517\/14712598.5.11.1491","volume":"5","author":"Mease","year":"2005","unstructured":"Mease PJ (2005) Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 5: 1491\u20131504","journal-title":"Expert Opin Biol Ther"},{"key":"1338_CR26","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin TST et al. (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 52: 3279\u20133289","journal-title":"Arthritis Rheum"},{"key":"1338_CR27","first-page":"48","volume":"arthritis","author":"Mease","year":"2005","unstructured":"Mease P, Gladman D, Richtlin C et al. (2005) Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT. ACR, Annual Scientific Meeting, San Diego, California, November 12\u201317","journal-title":"Clinical efficacy and safety of adalimumab for psoriatic"},{"key":"1338_CR28","unstructured":"Menter MA, Gordon KB, Leonardi C et al. (2005) Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis. AAD, Annual Scientific Meeting, San Diego, California, November 12\u201317"},{"key":"1338_CR29","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1111\/j.1396-0296.2004.04045.x","volume":"17","author":"Patel","year":"2004","unstructured":"Patel T, Gordon KB (2004) Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 17: 7442\u20137431","journal-title":"Dermatol Ther"},{"key":"1338_CR30","unstructured":"Patel T, Leonardi C, Kang S, Gordon K (2005) Treatment with adalimumab induces rapid normalization of epidermal keratinocytes in psoriasis patients. J Am Acad Dermatol 52 [Suppl]: P2816"},{"key":"1338_CR31","unstructured":"Robert Koch Institut (2005) Epidemiologisches Bulletin Hinweise zu Impfungen f\u00fcr Patienten mit Immundefizienz. Nr. 39"},{"key":"1338_CR32","unstructured":"Robert Koch Institut (2005) Epidemiologisches Bulletin Neuerungen in den aktuellen Impfempfehlungen der STIKO. Nr. 31"},{"key":"1338_CR33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/abio.2001.5380","volume":"299","author":"Santora","year":"2001","unstructured":"Santora LC, Kaymakcalan Z, Sakorafas P et al. (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography and BIAcore. Anal Biochem 299: 119\u2013129","journal-title":"Anal Biochem"},{"key":"1338_CR34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","volume":"4","author":"Scheinfeld","year":"2005","unstructured":"Scheinfeld N (2005) Adalimumab: a review of side effects. Expert Opin Drug Saf 4: 637\u2013641","journal-title":"Expert Opin Drug Saf"},{"key":"1338_CR35","first-page":"375","volume":"2","author":"Scheinfeld","year":"2003","unstructured":"Scheinfeld N (2003) Adalimumab (Humira): a review. J Drug Dermatol 2: 375\u2013377","journal-title":"J Drug Dermatol"},{"key":"1338_CR36","doi-asserted-by":"crossref","unstructured":"Schiff MH, Burmester GR, Kent JM et al. (2006) Safety analyses of adalimumab (Humira\u00ae) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis; published online","DOI":"10.1136\/ard.2005.043166"},{"key":"1338_CR37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"Schmitt","year":"2005","unstructured":"Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210: 194\u2013199","journal-title":"Dermatology"},{"key":"1338_CR38","first-page":"1310","volume":"103","author":"Schreiber","year":"2006","unstructured":"Schreiber St (2006) Ein erh\u00f6htes Krebsrisiko ist nicht hinreichend belegt. Meta-Analyse zur Therapie der rheumatoiden Arthritis mit Anti-TNF-Pr\u00e4paraten weist methodische Schw\u00e4chen auf. Dtsch Arztebl 103: 1310","journal-title":"Dtsch Arztebl"},{"key":"1338_CR39","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A et al. (2005) Psoriasis induced by anti-tumor necrosis factor therapy \u2013 a paradoxical adverse reaction. Arthritis Rheum 52: 2513\u20132518","journal-title":"Arthritis Rheum"},{"key":"1338_CR40","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1365-2133.2005.06520.x","volume":"152","author":"Sladden","year":"2005","unstructured":"Sladden MJ, Mortimer NJ, Hutchinson PE (2005) Extensive plaque psoriasis successfully treated with adalimumab (Humira\u00ae). Br J Dermatol 152: 1062\u20131094","journal-title":"Br J Dermatol"},{"key":"1338_CR41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1034\/j.1600-0625.2002.120414.x","volume":"12","author":"Tjioe","year":"2003","unstructured":"Tjioe M, Gerritsen MJP, Den Broder AA et al. (2003) Adalimumab, a fully human anti-TNF-\u03b1 monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patients. Exp Dermatol 12: 460\u2013465","journal-title":"Exp Dermatol"},{"key":"1338_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archderm.143.2.270","volume":"143","author":"Ubriani","year":"2007","unstructured":"Ubriani R, Voorhees AS van (2007) Onset of psoriasis during treatment with TNF\u03b1 antagonists: a report of 3 cases. Arch Dermatol 143: 270\u2013271","journal-title":"Arch Dermatol"},{"key":"1338_CR43","unstructured":"Vaszquez-Cobian LB, Flynn T, Agle LMA et al. (2003) Treatment of resistant uveitis in children with adalimumab. 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, Florida, October 23\u201328"},{"key":"1338_CR44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gut.2005.065417","volume":"54","author":"Vesga","year":"2005","unstructured":"Vesga L, Terdiman JP, Mahadevan U (2005) Adalimumab use in pregnancy. Gut 54: 890","journal-title":"Gut"},{"key":"1338_CR45","unstructured":"Vit\u00e9z L, Wozel G (2006) Adalimumab: complete clearing of skin lesions in a severe psoriatic arthritis patient. International Proceedings. 15th EADV Congress. Rhodos, 4.\u20138. Oktober, pp\u00a0785\u2013788"},{"key":"1338_CR46","unstructured":"Wallace K, Gordon K, Langley R et al. (2005) Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy. J Am Acad Dermatol 52 [Suppl]: P2734"},{"key":"1338_CR47","unstructured":"Wallace KL, Langley R, Bissonnette R et al. (2005) Quality of life in patients with psoriatic arthritis treated with adalimumab: subanalysis of studies in moderate to severe psoriasis. J Am Acad Dermatol 52 [Suppl]: P2783"},{"key":"1338_CR48","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","volume":"25","author":"Weisman","year":"2003","unstructured":"Weisman MH, Moreland LW, Furst DE et al. (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25: 1700\u20131721","journal-title":"Clin Ther"},{"key":"1338_CR49","unstructured":"Wozel G, Jahn S (2006) Biologics in der Dermatologie, 2. Aufl. UNI-MED Verlag AG, Bremen London Boston"},{"key":"1338_CR50","first-page":"ECR25","volume":"88","author":"Ziakas","year":"2003","unstructured":"Ziakas PD, Giannouli S, Tzioufas AG, Voulgarelis M (2003) Lymphoma development in a patient receiving anti-TNF therapy. Haematologica 88: ECR25","journal-title":"Haematologica"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-007-1338-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-007-1338-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-007-1338-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:15Z","timestamp":1558582635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-007-1338-5"}},"subtitle":["Adalimumab"],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s00105-007-1338-5","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}